$PG

Procter & Gamble Has Raised Its Dividend for 70 Years. These 2 Stocks Share Its Advantage

Procter & Gamble (PG) raised its dividend for the 70th consecutive year, with a forward yield of 2.75%. It generated $15.8B in free cash flow in 2026, covering 63% of dividends. Johnson & Johnson (JNJ) offers a 2.09% yield, with strong free cash flow coverage. PepsiCo (PEP) provides the highest yield at 4.50%, but with tighter coverage. All three companies maintained dividend growth through economic downturns.

Original reporting
Published Oct 17, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 17, 2026, 2:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Procter & Gamble Has Raised Its Dividend for 70 Years. These 2 Stocks Share Its Advantage — source image
Decision brief

The 30-second read

$PGBullishLow
01

Why it matters

Provides fresh quantitative updates on cash flow and dividend plans, reinforcing the defensive appeal of these stocks.

02

Market read

The updates underscore the attractiveness of dividend‑paying consumer staples for income‑oriented portfolios.

03

What to watch

Potential cost inflation and margin compression could limit future dividend sustainability.

Relevance 4/10Novelty 3/10Timing: today

Background

The article reviews three Dividend Kings—P&G, Johnson & Johnson, and PepsiCo—detailing their latest dividend hikes, cash‑flow metrics, and outlooks.

Company-level read

Ticker impact

$PGBullishHigh confidence
Context

P&G announced its 70th consecutive annual dividend increase and reported FY 2026 free cash flow of $15.835 bn.

Expected impact

likely modest upside as income‑focused investors add positions

Evidence & confidence

Dividend increase and cash generation reinforce the stock's low‑beta, income‑seeking appeal.

$JNJBullishHigh confidence
Context

Johnson & Johnson confirmed a 64th consecutive dividend increase and reaffirmed FY 2026 free cash flow guidance of about $21 bn.

Expected impact

potential slight rally from dividend‑seeking investors

Evidence & confidence

Consistent cash flow and dividend growth keep JNJ attractive for defensive portfolios.

$PEPNeutralMedium confidence
Context

PepsiCo reported its 54th consecutive dividend increase and FY 2026 dividend plan of $7.9 bn.

Expected impact

limited movement; investors weigh yield against margin pressure

Evidence & confidence

Yield appeal is offset by weaker cash‑flow cushion and slowing North American margins.

Market effects

Highlights the resilience of consumer‑staples dividend kings, supporting defensive sector sentiment.

U.S. large‑cap defensive stocks may see modest buying pressure.

Limited; primarily relevant to income‑focused investors worldwide.

Counterpoint

Yield‑seeking investors might prefer higher‑growth sectors as dividend growth slows.

Key entities

  • Procter & Gamble

    Consumer staples giant with 70 consecutive dividend increases.

  • Johnson & Johnson

    Healthcare conglomerate with 64 consecutive dividend increases.

  • PepsiCo

    Food and beverage leader with 54 consecutive dividend increases.

Related articles

$JNJHighAI 8/10

Johnson & Johnson (JNJ) Shares Fall 5.73% Despite Strong Q3 Earn

Johnson & Johnson (JNJ) shares fell 5.73% despite Q3 earnings beating expectations. The company reported adjusted EPS of $2.59 and revenues of $25.40 billion, a 5.9% YoY increase. JNJ raised full-year guidance but faced pressure from a $5.5 billion talc charge and slowing growth in key segments. The stock has a 2.04% dividend yield and a GF Score of 83/100, but is trading 31.4% above its intrinsic value.

$JNJHighAI 8/10

Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.

Johnson & Johnson (JNJ) reported Q3 revenue of $25.9B and EPS of $2.59, beating estimates, but shares fell 6% due to weak medical device sales. The company raised its 2026 sales and earnings guidance. JNJ's medical tech division, about 1/3 of total sales, underperformed, with CEO hinting at a potential spinoff of its orthopedics business. Despite this, JNJ's oncology business grew 16% YoY, driven by key drugs like Darzalex, Rybrevant, and Tecvayli.

$PEPHigh

KFC Drops Pepsi for Coke After Nearly 40 Years, and Analysts Put $500M in Annual Sales at Stake

KFC will switch from Pepsi to Coca-Cola in US restaurants, starting in January 2027. Bank of America analysts estimate this move could impact $500M in annual sales for Pepsi's North American beverage business, about 3% of its concentrate sales. Coca-Cola aims to expand its reach and brand visibility through this partnership, which KFC says is part of a menu refresh effort.

$YUMMed

KFC replaces PepsiCo with Coca-Cola across US restaurants by 2027

KFC will replace PepsiCo with Coca-Cola as its beverage supplier in US restaurants by Q1 2027, ending a 40-year partnership. The change aims to refresh the menu and attract more customers, according to KFC US president Catherine Tan-Gillespie. PepsiCo will remain a partner for KFC's international operations and parent company Yum Brands.